iiinova — where your digital self keeps evolving

Reposted by Mark Robson

Popehat @kenwhite.bsky.social · 20/01/2025

Not everyone can fight Trumpism and Trumpists directly. But remember this: kindness, decency, and fidelity to American values are defiance in the face of Trumpism. So be kind, decent, and faithful, particularly to the many kinds of people despised and attacked by Trumpists. That’s revolutionary./1

13187482188

Reposted by Mark Robson

Sarah Sammons MD @drsarahsammons.bsky.social · 11/12/2024

The next big thing in Triple Negative Breast Cancer: VEGF/PD-1 Bispecifics. Wonderful discussion by Dr. Thomas Grinda on the prospects. Several Phase III studies planned. @oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

0249

Reposted by Mark Robson

Maryam Lustberg MD MPH FASCO @maryamlustberg.bsky.social · 11/12/2024

Building on previous reported studies, endocrine therapy plus targeted for the win. (PADMA Trial). #bcsm #sabcs24

0123

Reposted by Mark Robson

Sarah Sammons MD @drsarahsammons.bsky.social · 11/12/2024

Dr. Waks from @dfcibreastonc.bsky.social presents MARGOT assessing margetuzumab, pertuzumab, taxane versus trastuzumab, pertuzumab, taxane in Stage II/III HER2+ disease. No statistically significant improvement in pCR. However, pCR in ER-, HER2+ w/ 12 wks of THP is >70% supporting de-escalation.

093

Reposted by Mark Robson

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · 09/12/2024

Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (December 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

034

Reposted by Mark Robson

Yael David @yaeldavidmsk.bsky.social · 04/12/2024

So excited to share our new paper working w/ David Lyden, Han Kim & Jackie Bromberg (WCM), led by the amazing Inbal Wortzel & Ifé Akano where we revealed a new & unexpected function for chromatin on the surface of exosomes in #cancer #metastasis @ Nature Cancer! www.nature.com/articles/s43...

nature.com

Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression - Nature Cancer

Lyden and colleagues find that immune developmental genes, such as apoptotic peptidase activating factor 1 (APAF1), support DNA packaging on the surface of tumor-derived extracellular vesicles that ar...

78219

Mark Robson @markrobsonmd.medsky.social · 25/11/2024

That is funny. I found a new vocation late in life.

020

Mark Robson @markrobsonmd.medsky.social · 25/11/2024

Starting the week in NYC with nuns on bikes!

1172

Mark Robson @markrobsonmd.medsky.social · 25/11/2024

The day you stop wanting to cry is the day you need to quit. I’ve been at this 33 years and it still kills me to say goodbye at the last visit before someone goes to hospice.

0161

Reposted by Mark Robson

Jame Abraham, MD, FACP @jameabraham.bsky.social · 24/11/2024

Let's get ready to be kind: to do our small part in lessen the suffering from hunger hcwvshunger.org amazing work by @tmprowell.bsky.social @shematologist.bsky.social #Oncsky is team #DiagnoseAndTreats The fundraising starts #Thanksgiving day #HCWvsHunger @fumikochino.bsky.social

33311

Reposted by Mark Robson

Timothy Snyder @timothysnyder.bsky.social · 23/11/2024

Lesson 1: Do not obey in advance. Thread of lessons from my book #OnTyranny. Written in 2016.

31892023412

Reposted by Mark Robson

Gregory Riely @rielymd.bsky.social · 21/11/2024

Paper looking at rates of accruals to phase 3 clinical trials across disciplines and sizes. Sobering numbers for oncology trials: Average of 127 sites per trial Average enrollment of 0.77 patients per month per site. Trials by top 20 pharma had slower recruitment www.nature.com/articles/d41...

nature.com

Benchmarking recruitment rates for phase III trials

Discover the world’s best science and medicine | Nature.com

1166

Reposted by Mark Robson

Morgan J Freeman @mjfree.bsky.social · 18/11/2024

“We can disagree and still love each other unless your disagreement is rooted in my oppression and denial of my humanity and right to exist” - James Baldwin

7559690314927

Mark Robson @markrobsonmd.medsky.social · 18/11/2024

I haven’t used Gemini. I have subscriptions to ChatGPT and Claude. I find them both helpful but agree with need to verify outputs. I find that they are more often incomplete than hallucinatory.

000

Reposted by Mark Robson

Dr. Don S Dizon @drdonsdizon.bsky.social · 16/11/2024

Finishing up a trip to Portugal, where I talked on social media in Oncology. I got a question about whether there was an ethical argument for why clinicians should be on social media. My answer: I do think there is an ethical imperative. 1/5

1129

Mark Robson @markrobsonmd.medsky.social · 15/11/2024

#Medsky friends. I want to give an introduction to LLMs to my groups. Open question for all of you - are there particular ways that you have found LLMs to be helpful? I have a sense of the challenges (hallucination, etc). I’m curious about positive ways people are using them at work.

110

Reposted by Mark Robson

Central Bylines @centralbylines.co.uk · 13/11/2024

Hello BlueSky. We had held off starting a dedicated channel to see how BlueSky evolved instead posting all of our 10 Bylines on @bylinesnetwork.bsky.social, but given how fast BlueSky is growing, now is the time to make the jump. Please help spread the word that Central Bylines are now here

27903545

Mark Robson @markrobsonmd.medsky.social · 13/11/2024

Welcome. Much nicer than That Other Place!

130

Reposted by Mark Robson

Tatiana Prowell, MD @tmprowell.bsky.social · 12/11/2024

NEW #Oncology: EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization) Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models #DrugDevelopment #OncoSky www.cell.com/cell-reports...

cell.com

EGFR-directed antibodies promote HER2 ADC internalization and efficacy

Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...

35213

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

But I am definitely an outlier here.

110

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

Hi! Good to be back. The Other Place was just so ugly that I withdrew completely. Anyway, this is my reservation with moderate risk testing “for family”. First, rates of cascade testing are awful, ⬇️ actual benefit. Second, risk prediction hard because ⬆️ spread of risk c/t B1/2. Third - mismanagement

110

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

I always have many thoughts about this. The question is whether one really needs to test over age 60-65 to find BRCA1/2/PALB2. I know it’s very contrarian but IMO “missing” things like CHEK2 and ATM is probably not such a big deal since our ability to estimate individual risk is awful.

110

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

Great. So now we will have a fascist AI. Just great.

000

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

Hi there. Running from The Other Place

110

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

To be fair, it was 78% in the placebo group….

100

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

Could you toss me onto the list? Grateful.

130

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

I’m a service line chief (40 docs). I am all for wellness. And one’s people have to be feeling OK to be engaged. But I don’t think focusing on people’s *wellness* is the right path. Instead, I think it is focusing on helping them fulfill what they see as their *purpose.* Wellness will follow.

220

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

Short answer is no, in my opinion. MDs don’t like to think of themselves as being part of organizations, so tend not to value learning org skills (and aren’t taught, either). Could be wrong, of course..

120

Mark Robson @markrobsonmd.medsky.social · 12/11/2024

BlueSky was mentioned at the TBCRC meeting and a number of folks may have jumped on it.

020

Mark Robson @markrobsonmd.medsky.social · 11/11/2024

I’d be grateful to be added! Also @tmprowell.bsky.social if you don’t have her.

110

Mark Robson @markrobsonmd.medsky.social · 11/11/2024

INAVO120 study: PFS Gains but Added Toxicity: INAVO + PAL-FLV nearly doubled PFS (15 vs. 7.3 mos) in PIK3CA-mutated HR+ HER2- breast cancer. Increased toxicities: 80% had grade 3-4 neutropenia, 5.6% hyperglycemia, 5.6% stomatitis, 3.7% diarrhea, and 6.8% discontinued due to adverse events. #bcsm

230

Mark Robson @markrobsonmd.medsky.social · 11/11/2024

Thanks. My local free library (Block Island) is swamped with books (yay) so I have to find another. Can you point me to other organizations? I’ll check out freecycle!

110

Mark Robson @markrobsonmd.medsky.social · 11/11/2024

I have a lot of books that I would be happy to donate but I live in a city. How do I get them to where they could be useful?

200

Mark Robson @markrobsonmd.medsky.social · 11/11/2024

Good morning, all! Just landed here and looks pretty nice. Anyone else from #bcsm? Anyone have a breast oncology starter pack?

370